<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918940</url>
  </required_header>
  <id_info>
    <org_study_id>CHB21.03</org_study_id>
    <nct_id>NCT04918940</nct_id>
  </id_info>
  <brief_title>Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma</brief_title>
  <acronym>VAXIMAB</acronym>
  <official_title>Post-vaccination Immunization Against SARS-CoV-2 in Patients Undergoing Maintenance With Anti-CD20 Antibodies for Follicular Lymphoma (FL) or Mantle Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anti-CD20 monoclonal antibodies, rituximab (R) and obinutuzumab (G), are used as standard&#xD;
      maintenance therapy every 2 months for 2 to 3 years in patients with follicular lymphoma (FL)&#xD;
      or mantle cell lymphoma (MCL).&#xD;
&#xD;
      This treatment is associated with profound and prolonged B lymphopenia, hypogammaglobulinemia&#xD;
      and increased infections. Severe forms of COVID-19 on Rituximab with prolonged carriage of&#xD;
      the virus have been reported due to significant impairment of humoral immunity in this&#xD;
      context of maintenance therapy.&#xD;
&#xD;
      Therefore, during the COVID-19 epidemic, clinicians are faced with the question of whether to&#xD;
      discontinue maintenance therapy or continue treatment. However, the half-life of rituximab is&#xD;
      29 days and lymphopenia continues for up to 9-12 months after stopping injections. Therefore,&#xD;
      it is not clear that discontinuation of maintenance therapy will alter the risk of severe&#xD;
      SARS-CoV-2.&#xD;
&#xD;
      However, post-vaccination immunization against SARS-CoV-2 by an mRNA vaccine is not known in&#xD;
      this context of prolonged treatment with rituximab or obinutuzumab. It is however well&#xD;
      established that post-vaccination responses against diphtheria, tetanus, pneumococcus, HBV,&#xD;
      or influenza in particular are altered after anti-CD20 antibodies. If the humoral response is&#xD;
      crucial in the post-vaccination response, it is also suggested that the preservation of&#xD;
      innate immunity and the CD8 response, unaltered by anti-CD20, could also play an important&#xD;
      role in the post-vaccination response and virus clearance.&#xD;
&#xD;
      The aim of our study is to evaluate the humoral and post-vaccination T-cell response based on&#xD;
      serological data and T-cell production of interferon gamma in response to SARS-CoV-2 specific&#xD;
      antigens (Elispot interferon gamma) in this group of patients treated for lymphoma with a&#xD;
      long-term anti-CD20 antibody.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">May 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of COVID-19 vaccination immunity</measure>
    <time_frame>3 months</time_frame>
    <description>kinetics of anti-SARS-CoV-2 antibody titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of COVID-19 vaccination immunity</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of post-vaccination IFN gamma production</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse of lymphoma</measure>
    <time_frame>one year</time_frame>
    <description>number of relapse of lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections to SARS-Cov-2</measure>
    <time_frame>one year</time_frame>
    <description>number of SARS-Cov-2 infection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Post-vaccination immunity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Determination of COVID-19 vacciantion efficacy</intervention_name>
    <description>Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection</description>
    <arm_group_label>Post-vaccination immunity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age superior to 18 years old&#xD;
&#xD;
          -  Patient undergoing maintenance treatment for Mantle Cell Lymphoma or Follicular&#xD;
             Lymphoma treated with rituximab or obinutuzumab in complete remission or stable&#xD;
             disease between injection #1 and injection #13 or 19 (end of second year or third&#xD;
             year)&#xD;
&#xD;
          -  Inform consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of SARS-Cov-2 infection less than 3 months old&#xD;
&#xD;
          -  Progressive lymphoma&#xD;
&#xD;
          -  Contraindication SARS-Cov-2 vaccination (allergy)&#xD;
&#xD;
          -  Refusal of SARS-CoV-2 vaccination&#xD;
&#xD;
          -  Patient who has been off rituximab or obinutuzumab therapy for more than 6 months&#xD;
&#xD;
          -  Patient not covered by health system&#xD;
&#xD;
          -  Pregnant or nursing woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Jardin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Jardin, MD, PhD</last_name>
    <phone>+33232082465</phone>
    <email>fabrice.jardin@chb.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doriane Richard, PhD</last_name>
    <phone>+33232082985</phone>
    <email>doriane.richard@chb.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jardin Fabrice, Md,PhD</last_name>
      <phone>+33232082465</phone>
      <email>fabrice.jardin@chb.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Doriane Richard, PhD</last_name>
      <phone>+33232082985</phone>
      <email>doriane.richard@chb.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sars-Cov-2 immunization</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Obinutuzumab</keyword>
  <keyword>Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

